CFDE Data Portal | Search LYPLAL1-DT

	Label	Description
	LYPLAL1-DT Gene (Entity type)	ENSG00000228063 - LYPLAL1 divergent transcript
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE134191 3 V 1 METFORMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

LYPLAL1-DT

ENSG00000228063 - LYPLAL1 divergent transcript

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE134191 3 V 1 METFORMIN MOUSE DN

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 0 v 1 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.